ECE2018 ePoster Presentations Pituitary and Neuroendocrinology (36 abstracts)
1Center of the Scientific and Clinical Study of Endocrinology, Tashkent, Uzbekistan; 2Tashkent Paediatric Medical Institute, Tashkent, Uzbekistan.
Tashkent Pediatric Medical Institute, department of endocrinology, Center of the Scientific and Clinical Study of Endocrinology, department f neuroendocrinoloy, Ministry of Health of the Republic of Uzbekistan.
Republic of Uzbekistan, 100125, Tashkent, Mirzo Ulugbek str. 56
M.Yu. Shakirova, Yu.M. Urmanova
The aim: To study dynamics of indicators of the questionnaire of QoL AGHD at assessment of quality of life at patients in 3 months and 6 months after operation of transnasal pituitary adenomectomy by the replacement treatment growth hormone Djintropin.
Material and methods: The patients (men-10 and women-3, aged from 18 up to 45 years) who were on stationary and out-patient inspection in the Center of Endocrinology, were selected in group of patients with the diagnosed GH deficiency (n=13) and received treatment by growth hormone Djintropin.
Results: Against the background of replacement therapy of GR DjINTROPIN reliable increase in values of the IGF-1, GR levels in blood (P<0.05) in 3 months of treatment and respectively increase in values of the IGF-1, GR levels in blood (P <0.05) and also blood GR (P < 0.05) in 6 months has been recorded. Significant reliable increase in level of calcium (P < 0.05), phosphorus (P <0.001) and also increase in activity of alkaline phosphatase is noted (P < 0.01) indicating acceleration of processes of bone metabolism against the background of the carried-out therapy. Decrease in levels of the general cholesterol and Lipids is recorded that demonstrates beneficial effect of GR DJINTROPIN on lipid exchange.
Conclusions: Assessment of change of anthropometrical indicators against the background of the carried-out therapy of GH DJINTROPIN has shown normalization of indicators of QoL according to the questionnaire of QoL AGHD: 10.2±2.5 points (during 6 months). Against the background of replacement therapy of GR DJINTROPIN reliable increase in initially low values of the IGF-1, GH levels in blood (P <0.05) in 3 months of treatment and also increase in STH (P <0.05) in 6 months has been recorded.